SynthesisThe Journal of infection2020
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.
Synthesis in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,283 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comorbidities and Risk Score for Severity and Outcome in Patients With Infection by SARS-CoV-2.
Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens
Who cites it
1,283 citing papers in PubMed, 4 syntheses or guidelines pooled it, 2,176 citations in OpenAlex.
- Predictors of mortality in severe pneumonia patients: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Cardiovascular diseases as risk factors of post-COVID syndrome: a systematic review.BMC public health · 2024Pooled it
- Risk Factors Associated with Severity and Death from COVID-19 in Iran: A Systematic Review and Meta-Analysis Study.Journal of intensive care medicine · 2023Pooled it
- Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis.BMC public health · 2023Pooled it
- Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer.BMC cancer · 2024Trial
- Trial
- Association of substance use with outcomes in mildly ill COVID-19 outpatients.The American journal of emergency medicine · 2023Trial
- Classifying healthcare facilities as predictors of COVID-19 mortality rates in US counties (2020-2021).Journal of public health (Oxford, England) · 2026Article
- Serum Apelin-13 and Galectin-3 in COVID-19: Associations With Routine Biochemical Parameters and Diagnostic Performance in a Case-Control Study.Journal of clinical laboratory analysis · 2026Article
- The Association Between Peak IL-6 Levels, In-Hospital Mortality, and Selected Risk Factors in Patients Hospitalized for COVID-19 at the Temporary Hospital in Gdansk-A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Long-term cognitive outcomes after mild COVID-19, critical COVID-19, and non-COVID critical illness: a prospective cohort comparison.Scientific reports · 2026Observational
- Chronic Conditions as Risk Factors for COVID-19-Associated Hospitalization Among Adults, 2020-2023.American journal of preventive medicine · 2026Article
- Live attenuated vaccination protects aged chimeric ACE2 mice from severe SARS-CoV-2 pathogenicity in vivo.PLoS pathogens · 2026Article
- A Unique Patient Stratification Method Combined with a Machine Learning Approach Identifies Novel Genetic Susceptibility and Protective Factors for Severe COVID-19 in a Hungarian Population.International journal of molecular sciences · 2026Article
- Evolution of outdoor sports during the COVID-19 post-lockdown in Spain: a nationwide population-based study.BMC public health · 2026Article
- Factors Associated with Maternal Mortality from COVID-19 in Pernambuco, Brazil (2020-2021): A Case-Control Study.Diseases (Basel, Switzerland) · 2026Article
- Beyond healthcare access: social deprivation and COVID-19 outcomes in dialysis patients in the provence-alpes-côte d'Azur region, France.BMC infectious diseases · 2026Article
- Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study.medRxiv : the preprint server for health sciences · 2026Article
- One-Year Survival and Changes in Care Needs Among Hospitalized Older Patients With Coronavirus Disease 2019 in Japan: A Nara Kokuho Database Analysis.Geriatrics & gerontology international · 2026Article
- Thrombotic thrombocytopenic purpura: a Trojan horse of acute leukemia?: a case report.Journal of medical case reports · 2026Article
1,223 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 and triggered a Public Health Emergency of International Concern (PHEIC). We aimed to find risk factors for the progression of COVID-19 to help reducing the risk of critical illness and death for clinical help.
methodsThe data of COVID-19 patients until March 20, 2020 were retrieved from four databases. We statistically analyzed the risk factors of critical/mortal and non-critical COVID-19 patients with meta-analysis.
resultsThirteen studies were included in Meta-analysis, including a total number of 3027 patients with SARS-CoV-2 infection. Male, older than 65, and smoking were risk factors for disease progression in patients with COVID-19 (male: OR = 1.76, 95% CI (1.41, 2.18), P < 0.00001; age over 65 years old: OR =6.06, 95% CI(3.98, 9.22), P < 0.00001; current smoking: OR =2.51, 95% CI(1.39, 3.32), P = 0.0006). The proportion of underlying diseases such as hypertension, diabetes, cardiovascular disease, and respiratory disease were statistically significant higher in critical/mortal patients compared to the non-critical patients (diabetes: OR=3.68, 95% CI (2.68, 5.03), P < 0.00001; hypertension: OR = 2.72, 95% CI (1.60,4.64), P = 0.0002; cardiovascular disease: OR = 5.19, 95% CI(3.25, 8.29), P < 0.00001; respiratory disease: OR = 5.15, 95% CI(2.51, 10.57), P < 0.00001). Clinical manifestations such as fever, shortness of breath or dyspnea were associated with the progression of disease [fever: 0R = 0.56, 95% CI (0.38, 0.82), P = 0.003;shortness of breath or dyspnea: 0R=4.16, 95% CI (3.13, 5.53), P < 0.00001]. Laboratory examination such as aspartate amino transferase(AST) > 40U/L, creatinine(Cr) ≥ 133mol/L, hypersensitive cardiac troponin I(hs-cTnI) > 28pg/mL, procalcitonin(PCT) > 0.5ng/mL, lactatede hydrogenase(LDH) > 245U/L, and D-dimer > 0.5mg/L predicted the deterioration of disease while white blood cells(WBC)<4 × 10
conclusionMale, aged over 65, smoking patients might face a greater risk of developing into the critical or mortal condition and the comorbidities such as hypertension, diabetes, cardiovascular disease, and respiratory diseases could also greatly affect the prognosis of the COVID-19. Clinical manifestation such as fever, shortness of breath or dyspnea and laboratory examination such as WBC, AST, Cr, PCT, LDH, hs-cTnI and D-dimer could imply the progression of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.